心血管诊断市场（2026—2031）
Mordor 预计，心血管诊断市场规模将由2026年的269.2亿美元增至2031年的351.9亿美元，期间复合年增长率为5.50%。2025年心电图系统占52.56%，冠心病诊断占58.66%，医院与卫生系统占63.56%。北美为最大市场，亚太地区增长最快。
市场研究正文
规模、增长、细分、驱动因素与关键问题
当前质量分 100.00，审核状态 accepted。结构化字段已按 RoboInd 内容层级组织。
核心结论
Mordor 预计，心血管诊断市场规模将由2026年的269.2亿美元增至2031年的351.9亿美元，期间复合年增长率为5.50%。2025年心电图系统占52.56%，冠心病诊断占58.66%，医院与卫生系统占63.56%。北美为最大市场，亚太地区增长最快。
市场走势
结构化指标
| 指标 | 年份 | 数值 | 性质 |
|---|---|---|---|
| 复合年增长率 | 2031 | 5.5% | 机构预测 |
| 市场规模 | 2026 | USD 26.92 billion | 机构预测 |
| 市场规模 | 2031 | USD 35.19 billion | 机构预测 |
细分市场份额
市场结构
| 维度 | 细分项 | 年份 | 份额 |
|---|---|---|---|
| disease | Coronary Artery Disease | 2025 | 58.660% |
| end_user | Hospitals & Health Systems | 2025 | 63.560% |
| geography | North America | 2025 | 39.440% |
| point-of-care_testing | Analyzers | 2025 | 47.760% |
关键结论
- disease 维度中，Coronary Artery Disease 在 2025 年的公开份额为 58.66%。
- end_user 维度中，Hospitals & Health Systems 在 2025 年的公开份额为 63.56%。
- geography 维度中，North America 在 2025 年的公开份额为 39.44%。
- point-of-care_testing 维度中，Analyzers 在 2025 年的公开份额为 47.76%。
主要参与者
- Becton, Dickinson and Company
- bioMérieux SA
- Bio-Rad Laboratories, Inc.
- F. Hoffmann-La Roche Ltd
- Thermo Fisher Scientific Inc.
增长驱动因素
| 因素 | 影响 CAGR | 地区相关性 | 影响周期 |
|---|---|---|---|
| Rising cardiovascular disease burden and population aging | +1.300% | Global | Long term (≥ 4 years) |
| High-sensitivity cardiac biomarker adoption | +1.000% | North America and Europe, growing in Asia-Pacific | Medium term (2-4 years) |
| Point-of-care and decentralized testing | +0.900% | Global, strongest in Asia-Pacific and Middle East & Africa | Short term (≤ 2 years) |
| AI-enabled imaging and electrocardiography | +0.800% | North America and Europe | Medium term (2-4 years) |
| Hospital-to-home diagnostic continuity | +0.600% | North America and Europe | Medium term (2-4 years) |
| Ambient-temperature assays and tier-2 and tier-3 distribution | +0.400% | Asia-Pacific, Middle East & Africa, and South America | Long term (≥ 4 years) |
市场制约因素
| 因素 | 影响 CAGR | 地区相关性 | 影响周期 |
|---|---|---|---|
| High capital cost and workflow-integration complexity | -0.700% | Global, most severe in Middle East & Africa and South America | Long term (≥ 4 years) |
| Reimbursement pressure and evidence uncertainty | -0.500% | North America and Europe | Medium term (2-4 years) |
| False-positive cascades from multimodal ai and biomarker testing | -0.400% | North America and Europe | Medium term (2-4 years) |
| Cybersecurity, algorithm drift, and interoperability liability | -0.300% | Global | Long term (≥ 4 years) |
报告关注的关键问题
What is the projected value of cardiovascular diagnostics by 2031?
The cardiovascular diagnostics market is forecast to reach USD 35.19 billion by 2031, from USD 26.92 billion in 2026, at a 5.50% CAGR.
Which product category leads cardiovascular diagnostics?
Electrocardiography Systems led with 52.56% of revenue in 2025 because they are used across resting, ambulatory, and implantable monitoring.
Which cardiovascular diagnostic product is growing fastest?
Echocardiography Systems is forecast to grow at a 7.15% CAGR through 2031, supported by automation and wider use of 3D and 4D imaging.
Why are cardiac biomarker tests becoming more important?
High-sensitivity troponin testing can help clinicians rule out acute myocardial infarction earlier and supports faster emergency department decisions.
Which region will grow fastest through 2031?
Asia-Pacific is forecast to grow at an 8.88% CAGR, supported by health infrastructure investment, diagnostic chain expansion, and older populations.
What is the largest end-user group for cardiovascular diagnostic systems?
Hospitals & Health Systems held 63.56% of revenue in 2025 because they provide emergency care, imaging, electrophysiology, and structural heart services.
市场概览
- 增长最快市场：亚太地区
- 最大市场：北美
- 市场集中度：中等
查看来源：Mordor Intelligence